Publicaciones en colaboración con investigadores/as de Università degli Studi di Brescia (26)

2024

  1. Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure

    American Heart Journal, Vol. 267, pp. 52-61

2023

  1. Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry

    European journal of preventive cardiology, Vol. 30, Núm. 13, pp. 1346-1358

  2. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 25, Núm. 4, pp. 457-468

  3. Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry

    European Heart Journal, Vol. 44, Núm. 17, pp. 1526-1529

  4. Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 1049-1060

  5. Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: An analysis from the ESC-HFA Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 1061-1071

  6. Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery

    European Journal of Heart Failure, Vol. 25, Núm. 12, pp. 2316-2330

  7. Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial

    JACC: Heart Failure, Vol. 11, Núm. 12, pp. 1729-1738

2022

  1. Assessment of Omecamtiv Mecarbil for the Treatment of Patients with Severe Heart Failure: A Post Hoc Analysis of Data from the GALACTIC-HF Randomized Clinical Trial

    JAMA Cardiology, Vol. 7, Núm. 1, pp. 26-34

  2. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology

    European journal of preventive cardiology, Vol. 29, Núm. 1, pp. 275-300

  3. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology

    European Journal of Heart Failure, Vol. 24, Núm. 1, pp. 143-168

2021

  1. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

    European Heart Journal, Vol. 42, Núm. 36, pp. 3599-3726

  2. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

    New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116

  3. Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary

    European Journal of Heart Failure, Vol. 23, Núm. 10, pp. 1597-1609

  4. HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community

    ESC Heart Failure, Vol. 8, Núm. 6, pp. 4394-4408

  5. HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge

    ESC Heart Failure, Vol. 8, Núm. 6, pp. 4425-4443

  6. Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department

    ESC Heart Failure, Vol. 8, Núm. 6, pp. 4409-4424

2020

  1. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 22, Núm. 8, pp. 1424-1437

  2. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

    European Journal of Heart Failure, Vol. 22, Núm. 11, pp. 2160-2171

2019

  1. Effects of serelaxin in patients with acute heart failure

    New England Journal of Medicine, Vol. 381, Núm. 8, pp. 716-726